Philips and icometrix advance precision diagnosis in neurology with innovative AI-based imaging solutions at #RSNA24
25 11월 2024 - 11:00PM
November 25, 2024icometrix’ FDA-cleared quantitative brain
solution for neurological conditions including Alzheimer’s and
multiple sclerosis is seamlessly integrated into Philips next
generation BlueSeal MR scanners, and will be deployed in its
comprehensive informatics platformAmsterdam, the
Netherlands and Leuven, Belgium – Royal Philips (NYSE:
PHG, AEX: PHIA), a global leader in health technology, and
computer-aided diagnostics company icometrix (Leuven, Belgium) have
teamed up to deploy an AI-driven, end-to-end solution for
acquiring, reading, and reporting the results of MRI brain scans to
optimize diagnosis and treatment monitoring of neurological
conditions including Alzheimer’s and multiple sclerosis (MS).
Unveiled at RSNA 2024, icometrix’s unique AI-powered quantitative
reporting software is seamlessly integrated into Philips’ latest
BlueSeal MR scanners through Philips’ new Smart Reading capability
[1], providing consistent and more accurate diagnosis. The software
will also be deployed on Philips’ healthcare informatics platform –
including Philips cloud-based AI Manager.The introduction of new
drugs that slow the progression of Alzheimer’s emphasizes the
critical role of MRI in patient management. By leveraging advanced
MRI techniques, neurologists can identify the most suitable
candidates for these therapies, ensuring timely and personalized
treatment. AI's ability to extract quantitative measurements from
brain scans enhances the diagnostic process, enabling quicker
decision making and improved monitoring of disease progression.
This integration of technology increases efficiency for healthcare
providers and leads to more tailored treatment.“Philips is at the
forefront of applying AI to help save time and improve diagnostic
accuracy so clinicians can deliver better care to more patients,”
said Shez Partovi, Chief Innovation & Strategy Officer at
Philips. “As these innovations continue to evolve, they hold great
promise for transforming the landscape of neurological care,
offering hope for better management of chronic conditions like
Alzheimer’s and MS. Our partnership with icometrix is an important
step forward in the use of AI to help mitigate staff shortages,
lower the cost of care, increase diagnostic confidence, and
facilitate care orchestration of personalized plans for the growing
number of people who are diagnosed with Alzheimer's disease."“Our
icobrain imaging AI measures are rapidly becoming the standard of
care for diagnosis and monitoring of neurological conditions,” said
Wim Van Hecke, CEO of icometrix. “MRI quantification is crucial to
unlock precision medicine, especially in the Alzheimer’s disease
care pathway, which is why our partnership with Philips is so well
timed. We have developed the leading AI solutions for brain MRI
monitoring, received CPT III code reimbursement in the US, and we
will be able to support radiologists, neurologists, and people with
neurological conditions at scale through this
collaboration.”Managing the growing volume of Alzheimer’s
imaging results Alzheimer’s is the most common form
of dementia, accounting for 60% to 70% of the 55 million dementia
cases worldwide [2], with more than 150 million people likely to be
living with dementia, predominantly Alzheimer’s, by 2050 [3]. With
the introduction of monoclonal antibody drugs that break down the
amyloid protein deposits in the brain that are believed to be the
cause of Alzheimer’s, MRI is now crucial as a part of the
diagnostics process as well as to assess treatment effectiveness
and help avoid adverse side effects. The latest guidelines for
using these drugs involve a minimum of four separate MRI scans
during the first year of treatment. High caseloads and the global
shortage of neuroradiologists – coupled with the time-consuming
nature of manual image reading and difficulty in extracting
consistent quantitative measurements – is already putting a severe
burden on radiology departments.In addition to icometrix’s icobrain
dm software for differential dementia diagnosis, the solution also
includes the company’s icobrain ARIA software [4]. The only
FDA-cleared solution that is classified as computer-aided detection
and diagnosis, Icobrain ARIA can detect and grade the severity of
amyloid-related imaging abnormalities. Icobrain ARIA quantifies, in
a fully automated way, the extent of a potentially fatal side
effect of anti-amyloid drugs known as amyloid-related imaging
abnormalities (ARIA) – typically fluid buildup in the brain or
blood leakage into brain tissue. Monitoring ARIA over the course of
therapy allows neurologists to adjust a patient’s therapy to
minimize these side effects. Philips’ latest BlueSeal MR
scanners are delivered with standardized AI-based SmartExam
planning and AI-accelerated SmartSpeed protocols to image ARIA
quickly and easily. Philips unique Smart Reading software [4] also
allows end-to-end seamless integration of imaging protocols with
the icometrix icobrain ARIA software to deliver fast, fully
automated, quantitative outcomes for Alzheimer’s patients.
Integrated into Philips’ healthcare informatics platform,
these breakthrough AI-driven diagnostic and therapy monitoring
capabilities fit seamlessly into radiology MR workflows and
hospital PACS.Speeding the differential diagnosis of
multiple sclerosisTo ensure more confident diagnosis of
MS, new clinical guidelines have been introduced that include a
special MR imaging protocol and FLAIR* generation in Philips
Advanced Visualization Workspace to simultaneously create
high-quality images of white matter lesions and veins. Philips is
currently the only commercial supplier of MR scanners that can
perform FLAIR* imaging. icometrix icobrain ms, also seamlessly
integrates on the Philips MR scanner and Philips AI Manager. It
counts the number of white-matter lesions forming around veins – a
characteristic highly specific to MS and it also allows for
longitudinal and quantitative comparison of follow-up MRI exams,
which are essential for treatment decision-making.Philips’ latest
neuroimaging solutions and icometrix’s software solutions for
Alzheimer’s and MS will be available on the Philips BlueSeal 1.5T
MR scanners and Philips’ 3.0T MR portfolio. The solutions will be
demonstrated in the Philips booth (6730) and the icometrix booth
(4903) at the Radiological Society of North America Annual Meeting
(RSNA 2024, December 1-4, Chicago, USA). For more information,
visit Philips at RSNA 2024.[1] BlueSeal XE/SE and Smart Reading is
not yet CE marked, not cleared in all countries, and not yet
available for delivery in any country. Please consult your
Philips contact person for further information.[2] World Health
Organization (WHO), Dementia Key Facts
https://www.who.int/news-room/fact-sheets/detail/dementia[3]
Nichols, Emma et al. Estimation of the global prevalence of
dementia in 2019 and forecasted prevalence in 2050: an analysis for
the Global Burden of Disease Study 2019. The Lancet Public Health,
Volume 7, Issue 2, e105 - e125
https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(21)00249-8/fulltext[4]
Philips and Icometrix have the intention to make icobrain aria
software available for reselling in the USA through the Philips
catalog, as well as a Smart Reading solution on MR platforms.
Philips AI Manager is not intended for data interpretation or
diagnosis. Availability of 3rd party algorithm may vary per market.
The functionalities and benefits of the solution depend on
customer-specific configuration and use. Please contact your local
Philips representative for market availability.
For further information, please contact:Kathy
O’ReillyPhilips Global External RelationsTel.: +1 978 221
8919E-mail: kathy.oreilly@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
well-being through meaningful innovation. Philips’ patient- and
people-centric innovation leverages advanced technology and deep
clinical and consumer insights to deliver personal health solutions
for consumers and professional health solutions for healthcare
providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in
diagnostic imaging, ultrasound, image-guided therapy, monitoring,
and enterprise informatics, as well as in personal health. Philips
generated 2023 sales of EUR 18.2 billion and employs approximately
69,300 employees with sales and services in more than 100
countries. News about Philips can be found at
www.philips.com/newscenter.
- MR technologist reviews icometrix AI report on the Philips
BlueSeal MRI console
- MR technologist reviews neuro images in icometrix AI reporting
tool
Koninklijke Philips NV (NYSE:PHG)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Koninklijke Philips NV (NYSE:PHG)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024